Table 1. Baseline characteristics for... | American Society of Hematology

Table 1.

Baseline characteristics for 821 patients with PTCL NOS, AITL, and ALCL treated in first-line with CHO(E)P with or without autologous SCT or other therapy

	Total		CHO(E)P with ASCT		CHO(E)P without ASCT		Other therapy
	N = 821		n = 178		n = 542		n = 101
	No.	%	No.	%	No.	%	No.	%
Male sex	497	61	109	61	336	62	52	51
Median age (range), y	64 (18-96)		56 (20-71)		67 (18-88)		70 (22-96)
Subtype
PTCL NOS	266	32	57	32	173	32	36	36
AITL	306	37	80	45	199	37	27	27
ALCL	249	30	41	23	170	31	38	38
ALK⁺	95	38	2	5	88	52	5	13
ALK^–	148	59	38	93	78	46	32	84
ALK unknown	6	3	1	2	4	2	1	3
Ann Arbor stage
I-II	173	21	28	16	108	20	37	37
III-IV	640	78	148	83	431	80	61	60
Unknown	8	1	2	1	3	1	3	3
Elevated LDH	417	51	86	48	296	55	35	35
WHO performance score
0-1	356	43	98	55	209	39	49	49
2-4	87	11	14	8	58	11	15	15
Unknown	378	46	66	37	275	51	37	37
>1 extranodal localization	160	19	39	22	108	20	13	13
IPI score
0-1	237	29	58	33	134	25	45	45
2	232	28	68	38	140	26	24	24
3-5	352	43	52	29	268	49	32	32

	Total		CHO(E)P with ASCT		CHO(E)P without ASCT		Other therapy
	N = 821		n = 178		n = 542		n = 101
	No.	%	No.	%	No.	%	No.	%
Male sex	497	61	109	61	336	62	52	51
Median age (range), y	64 (18-96)		56 (20-71)		67 (18-88)		70 (22-96)
Subtype
PTCL NOS	266	32	57	32	173	32	36	36
AITL	306	37	80	45	199	37	27	27
ALCL	249	30	41	23	170	31	38	38
ALK⁺	95	38	2	5	88	52	5	13
ALK^–	148	59	38	93	78	46	32	84
ALK unknown	6	3	1	2	4	2	1	3
Ann Arbor stage
I-II	173	21	28	16	108	20	37	37
III-IV	640	78	148	83	431	80	61	60
Unknown	8	1	2	1	3	1	3	3
Elevated LDH	417	51	86	48	296	55	35	35
WHO performance score
0-1	356	43	98	55	209	39	49	49
2-4	87	11	14	8	58	11	15	15
Unknown	378	46	66	37	275	51	37	37
>1 extranodal localization	160	19	39	22	108	20	13	13
IPI score
0-1	237	29	58	33	134	25	45	45
2	232	28	68	38	140	26	24	24
3-5	352	43	52	29	268	49	32	32

IPI, International Prognostic Index; LDH, lactate dehydrogenase; No., number.

View Large

This Feature Is Available To Subscribers Only